vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)vedomostiregmed-23Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYСТАТЬЯ ОТОЗВАНА: Аргиназа II - новая мишень для создания эндотелиопротекторовRETRACTED: Arginase II - a new target in the development of endothelium protectorsЯкушевВ. И.YakushevV. I.vladi-yakus@yandex.ruПокровскийМ. В.PokrovskyM. V.noemail@neicon.ruБесхмельницынаЕ. А.BeskhmelnitsynaE. A.noemail@neicon.ruМясищеваО. В.MyasishchevaO. V.noemail@neicon.ruЛитвиноваА. С.LitvinovaA. S.noemail@neicon.ruКривошаповаИ. И.KrivoshapovaI. I.noemail@neicon.ruДемченкоС. А.DemchenkoS. A.noemail@neicon.ruФедеральное государственное автономное образовательное учреждение высшего профессионального образования Национальный исследовательский университет «Белгородский государственный университет»РоссияFederal State Autonomous Educational Institution of Higher Professional Education Belgorod National Research University «Belgorod State University»Russian Federation201513022018012630Copyright © Якушев В.И., Покровский М.В., Бесхмельницына Е.А., Мясищева О.В., Литвинова А.С., Кривошапова И.И., Демченко С.А., 20182018Якушев В.И., Покровский М.В., Бесхмельницына Е.А., Мясищева О.В., Литвинова А.С., Кривошапова И.И., Демченко С.А.Yakushev V.I., Pokrovsky M.V., Beskhmelnitsyna E.A., Myasishcheva O.V., Litvinova A.S., Krivoshapova I.I., Demchenko S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/23

СТАТЬЯ ОТОЗВАНА

В обзоре рассмотрена роль аргиназы в патогенезе эндотелиальной дисфункции и ряда сердечно-сосудистых заболеваний. Аргиназа катализирует гидролиз L-аргинина, субстрата для синтеза оксида азота, до L-орнитина и мочевины. В организме человека обнаружены две изоформы аргиназы. Аргиназа I локализуется в цитоплазме клеток и экспрессируется преимущественно в печени. Аргиназа II - это митохондриальный белок, который экспрессируется в почках, простате, сосудистой стенке. Аргиназа II гидролизирует L-аргинин, снижая тем самым синтез оксида азота, приводит к развитию эндотелиальной дисфункции и возникновению целого ряда патологий сердечно-сосудистой системы. Аргиназа является перспективной фармакологической мишенью в коррекции эндотелиальной дисфункции и целого ряда сердечно-сосудистых заболеваний, однако создание высокоселективных ингибиторов аргиназы II по-прежнему остается трудноразрешимой задачей

RETRACTED ARTICLE

The article describes arginase’s role in pathogenesis of endothelial dysfunction and a number of cardio-vascular diseases. Arginase catalyzes the hydrolysis of L-arginine, the substrate for nitric oxide synthesis, to L-ornithine and urea. Two isoforms of arginase were found in the human organism. Arginase I is located in the cells cytoplasm and is predominantly expressed in the liver. Arginase II is a mitochondrial protein that is expressed in the kidney, prostatic gland and vascular wall. Arginase II hydrolyzes L-arginine, thereby reducing the synthesis of nitric oxide and leading to the development of endothelial dysfunction and a number of cardio-vascular disorders. Arginase is a promising pharmacological target in the treatment of endothelial dysfunction and a number of cardio-vascular diseases, though the development of highly-selective arginase II inhibitors is still a difficult task.

L-аргининаргиназа Iаргиназа IIэндотелиальная дисфункциядиабетгипертензияэндотелиальная синтаза оксида азотаL-argininearginase Iarginase IIendothelial dysfunctiondiabeteshypertensionendothelial nitric oxide synthaseReferencesБабко А.В., Покровский М.В., Терехова Е.Г. и др. Влияние сочетанного применения ингибитора аргиназы L-норвалина и фиксированной комбинации лозартана и гидрохлоротиазида в одной таблетке на эндотелиальную дисфункцию при экспериментальном моделировании L-NAME-индуцированного дефицита оксида азота. Кубанский научный медицинский вестник 2011 ; (4): 24-28.Babko AV, Pokrovsky MV, Terehova EG, et al. Effect of combined application of arginase inhibitor L-norvaline and the fixed combination of losartan and hydrochlorothiazide in one tablet on endothelial dysfunction in experimental L-NAME- induced deficiency of nitric oxide method modeling. Kuban Research Medical Journal 2011; (4): 24–28 (in Russian).Бокарев И.Н. Артериальная гипертония - болезнь или фактор риска? Клиническая медицина 2004; (9): 69-71.Bokarev IN. Is arterial hypertension disease or risk factor? Clinical medicine 2004; (9): 69–71 (in Russian).Покровская Т.Г. Использование L-аргинина в профилактике нарушений функции эндотелия в условиях ингибирования эндотелиальной и индуцибельной NO-синтаз. Аллергология и иммунология 2008; 9(3): 328.Pokrovskaya TG, Kochkarov VI, Pokrovsky MV, et al. The use of L-arginine for the prevention of endothelial dysfunction in inhibiting endothelial and inducible NO- synthase. Allergology and Immunology 2008; 9(3): 328 (in Russian).Покровская Т.Г. Роль фармакологической коррекции метаболического пути L-аргинин/NO при моделировании дефицита оксида азота. Кубанский науч. мед. вестник 2008; (4): 122-125.Pokrovskaya TG. The role of pharmacological correction of L-arginine / NO pathway for modeling deficit of nitric oxide. Kuban Research Medical Journal 2008; (4): 122–125 (in Russian).Покровская Т.Г., Кочкаров В.И., Даниленко Л.М. и др. Эндотелиопротективное действие L-аргинина при фармакологическом способе для синтеза большого количества структурных белков (в том числе и коллагена) [33].Pokrovskaya TG, Kochkarov VI, Danilenko LM, et al. Endothelial protective effect of L-arginine in pharmacological deficiency of nitric oxide method modeling. Scientific statements of Belgorod State University 2006; 3(23): 43–51 (in Russian).Покровский М.В., Покровская Т.Г., Кочкаров В.И., Артюшкова Е.Б. Эндотелиопротективные эффекты L-аргинина при экспериментальном моделировании дефицита оксида азота. Экспериментальная и клиническая фармакология 2008; 71(2): 29-31.Pokrovsky MV, Pokrovskaya TG, Kochkarov VI, Artushkova EB. Endothelial protective effects of L-arginine in experimental modeling of nitric oxide deficit. Experimental and clinical pharmacology 2008; 71(2): 29–31 (in Russian).Солонин Д.Л., Сыренский А.В., Галагудза М.М. и др. Роль оксида азота в регуляции растяжимости артериальных сосудов у нормо- и гипертензивных крыс. Артериальная гипертензия 2002; (6): 57-64.Solonin DL, Syrensky AV, Galagudza MM, et al. The role of nitric oxide in the regulation of arterial distensibility vessels in normal and hypertensive rats. Artherial hypertension 2002; (6): 57–64 (in Russian).Цепелева С.А., Покровский М.В., Покровская Т.Г. Кардио- и эндотелиопротективные эффекты ингибитора аргиназы L-норвалина при моделировании L-NAME-индуцированного дефицита оксида азота. Кубанский научный медицинский вестник 2011; (4): 185-87.Tsepeleva SA, Pokrovsky MV, Pokrovskaya TG, et al. Cardiac and endothelial protective effects of arginase inhibitor L-norvaline in experimental L-NAMEinduced deficiency of nitric oxide method modeling. Kuban Research Medical Journal 2011; (4): 185–87 (in Russian).Berkowitz D., White R., et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; (108): 2000-2006.Berkowitz D, White R, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; (108): 2000–2006.Bivalacqua T., Hellstrom W., Kadowitz P., et al. Increased expression of arginase II in human diabetic corpus cavernosum in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun. 2001; (283): 923-27.Bivalacqua T, Hellstrom W, Kadowitz P, et al. Increased expression of arginase II in human diabetic corpus cavernosum in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun. 2001; (283): 923–27.Böger R.H. The pharmacodynamics of L-arginine. J Nutr. 2007; (137): 1650-55.Böger RH. The pharmacodynamics of L-arginine. J Nutr. 2007; (137): 1650–55.Chicoine L.G., Paffet M.L., Young T.L., et al. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2004; (287): 60-68.Chicoine LG, Paffet ML, Young TL, et al. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2004; (287): 60–68.Crombez E.A., Cederbaum S.D. Hyperargininemia due to liver arginase deficiency. Mol Genet Metabol. 2005; (84): 243-51.Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metabol. 2005; (84): 243–51.Demougeot C., Prigent-Tesssier A., Marie C., et al. Arginase inhibition reduced endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens. 2005; (23): 971-8.Demougeot C, Prigent-Tesssier A, Marie C., et al Arginase inhibition reduced endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens. 2005; (23): 971–8.Drexler H., Zeiher M., Meinzer K. Correction of endothelial dysfunction in coronary microcirculation of hypercholestrolemic patients by L-arginine. Lancet 1991; (67): 1301-08.Drexler H., Zeiher M., Meinzer K. Correction of endothelial dysfunction in coronary microcirculation of hypercholestrolemic patients by L-arginine. Lancet 1991; (67): 1301–08.Durante W., Johnson F.K., Johnson R.A., et al. Arginase induces endothelial dysfunction and hypertension in obese Zucker rats. Diabetes 2005; (54): 120-124.Durante W, Johnson FK, Johnson RA, et al. Arginase induces endothelial dysfunction and hypertension in obese Zucker rats. Diabetes 2005; (54): 120–124.Hein T.W., Zhang C., Wang W. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003; (17): 2328-30.Hein TW, Zhang C, Wang W. Ischemia-reperfusion selectively impairs nitric oxide- mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003; (17): 2328–30.Ignarro L.J., Buga G.M., Wei L.H. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; (98): 4202-08.Ignarro LJ, Buga GM, Wei LH. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; (98): 4202–08.Iyer R.K., Yoo P.K., Kern R.M., et al. Mouse model for human arginase deficiency. Mol Cell Biol 2002; (22): 4491-98.Iyer RK, Yoo PK, Kern RM, et al. Mouse model for human arginase deficiency. Mol Cell Biol 2002; (22): 4491–98.John S., Schmeider R.E. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003; (5): 199-207.John S, Schmeider RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003; (5): 199–207.Johnson F.K., Johnson R.A., Peyton K.J., et al. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2005; (288): 1057-62.Johnson FK, Johnson RA, Peyton KJ, et al. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2005; (288): 1057–62.Jung A.S., Wilson R.M., Houser S.R., et al. Modulation of contractility by myocyte-derived arginase in normal and hypertrophied feline myocardium. Am J Physiol Heart Circ Physiol. 2005; (34): 298-305.Jung AS, Wilson RM, Houser SR, et al. Modulation of contractility by myocytederived arginase in normal and hypertrophied feline myocardium. Am J Physiol Heart Circ Physiol. 2005; (34): 298–305.Kampfer H., Pfeilschifter J., Frank S. Expression and activity of arginase isozymes during normal and diabetic-impaired skin repair. J Invest Dermatol. 2003; (121):1544-51.Kampfer H, Pfeilschifter J, Frank S. Expression and activity of arginase isozymes during normal and diabetic-impaired skin repair. J Invest Dermatol. 2003; (121):1544–51.Kawamoto S., Amaya Y., Murakami K., et al. Complete nucleotide sequence of cDNA and deduced amino acid sequence of the rat liver arginase. Amaya J Biol Chem. 1987; (262): 6280-83.Kawamoto S, Amaya Y, Murakami K, et al. Complete nucleotide sequence of cDNA and deduced amino acid sequence of the rat liver arginase. Amaya J Biol Chem. 1987; (262): 6280–83.Lefer A., Lefer D.J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion. Cardiovas Res. 1996; (32): 743-51.Lefer A, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion. Cardiovas Res. 1996; (32): 743–51.Li H., Meininger C.J., Hawker J.R., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline synthesis in endothelial cells. Am J Physiol Endocrinol Metab. 2001; (280): 75-82.Li H, Meininger CJ, Hawker JR, et al . Regulatory role of arginase I and II in nitric oxide, polyamine, and proline synthesis in endothelial cells. Am J Physiol Endocrinol Metab. 2001; (280): 75–82.Loscalzo J. An experiment in nature: genetic L-arginine deficiency and NO insufficiency. J Clin Invest. 2001; (108): 663-64.Loscalzo J. An experiment in nature: genetic L-arginine deficiency and NO insufficiency. J Clin Invest. 2001; (108): 663–64.Loyaga-Rendon R., Sakamoto S., Beppu M., et al. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis. 2005; (178): 231-39.Loyaga-Rendon R, Sakamoto S, Beppu M, et al. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis. 2005; (178): 231–39.Meurs H., Maarsingh H., Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. TIPS 2003; (24): 450-54.Meurs H, Maarsingh H, Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. TIPS 2003; (24): 450–54.Morris C.R., Kato G.J., Poljakovic M., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and limited substrate availability in sickle cell disease. JAMA 2005; (294): 81-90.Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and limited substrate availability in sickle cell disease. JAMA 2005; (294): 81–90.Morris S.M., Bhamidipati D., Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression Gene. Mol Genet Metabol. 1997; (193): 157-61.Morris SM, Bhamidipati D, Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression Gene. Mol Genet Metabol. 1997; (193): 157–61.Shi O., Morris MS., Zoghbi H., et al. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol. 2001; (21): 811-13.Shi O, Morris MS, Zoghbi H, et al. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol. 2001; (21): 811–13.Teupser D., Burkhardt D.R., Wilfert W., Haffner I., et al. Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Thromb Vasc Biol. 2006; (26): 365-71.Teupser D, Burkhardt DR, Wilfert W, Haffner I, et al. Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Thromb Vasc Biol. 2006; (26): 365–71.Tousoulis D., Antoniades C., Tentolouris C. L-Arginine in cardiovascular disease: dream or reality? Vasc Med. 2002; (7): 203-11.Tousoulis D, Antoniades C, Tentolouris C. L-Arginine in cardiovascular disease: dream or reality? Vasc Med. 2002; (7): 203–11.Vockley J.G., Jenkinson C.P., Shukla H., et al. Cloning and characterization of the human type II arginase gene. Vockley 1996; (2): 118-23.Vockley JG, Jenkinson CP, Shukla H, et al. Cloning and characterization of the human type II arginase gene. Vockley 1996; (2): 118–23.White A.R., Ryoo S., Li D., et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2007; (19): 57-62.White AR, Ryoo S, Li D, et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2007; (19): 57–62.Xu W., Kaneko T., Zheng S., et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary artery hypertension. FASEB J. 2004; (18): 1746-1748.Xu W, Kaneko T, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary artery hypertension. FASEB J. 2004; (18): 1746–1748.Zhang C., Hein T.W., Wang W., et al. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001; (15): 1264-66.Zhang C, Hein TW, Wang W, et al. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001; (15): 1264–66.

The authors declare that there are no conflicts of interest present.